Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreren
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ASCENDIS PHARMA A/S

(ASND)
  Rapport
Vertraagde tijd Nasdaq  -  22:00:00 03-02-2023
116.10 USD   -1.39%
18/01Technologieaandelen leiden Europese aandelen licht hoger in de woensdaghandel
MT
17/01Farmaceutische aandelen leiden Europese aandelen hoger in de dinsdaghandel
MT
17/01Ascendis Pharma A/S : SVB Securities LLC herhaalt koopadvies voor het aandeel
MM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť ASCENDIS PHARMA A/S
09/01Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
PU
08/01Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Mor..
AQ
04/01Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma..
AQ
03/01Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
03/01Ascendis Pharma to Present at the 41st Annual†J.P. Morgan Healthcare Conference
AQ
2022Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
2022Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
PU
2022Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult ..
AQ
2022Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference
AQ
2022Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines A..
AQ
2022Dose Escalation Data from transcendIT-101 Ascendis Pharma's Phase 1/2 Trial of TransCon..
AQ
2022Once-Weekly TransCon CNP Achieved Primary Efficacy Objective, with Superiority at 100 -..
AQ
2022Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
PU
2022Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines A..
AQ
2022Ascendis Pharma A/s : TransCon™ CNP ACcomplisH Trial Topline Results
PU
2022Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority a..
AQ
2022Ascendis Pharma A/s : TransCon™ TLR7/8 Agonist Initial Results from Dose Escalation ..
PU
2022Dose Escalation Data from transcendIT-101, Ascendis Pharma's Phase 1/2 Trial of TransCo..
AQ
2022Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
2022Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
PU
2022Ascendis Pharma Reports Third Quarter 2022 Financial Results
AQ
2022FDA Accepts for Priority Review Ascendis Pharma's NDA for TransCon PTH in Adult Patient..
AQ
2022Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
PU
2022FDA Accepts for Priority Review Ascendis Pharma's NDA for TransCon™ PTH in Adult ..
AQ
2022Ascendis Pharma A/S Announces Third Quarter 2022 Financial Results and Business Update ..
AQ
2022Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
2022Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
PU
2022Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT..
AQ
2022Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
2022Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
2022New Long-Term Data in Adult Patients with Hypoparathyroidism Treated with Ascendis Phar..
AQ
2022Ascendis Pharma Submits TransCon PTH New Drug Application to the U.S. FDA for Adult Pat..
AQ
2022Ascendis Pharma A/S Announces Upcoming Investor Presentations in September
AQ
2022Ascendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Ad..
AQ
2022Ascendis Pharma A/s : Notice to convene Extraordinary General Meeting - Form 6-K
PU
2022Ascendis Pharma A/s : Reports Second Quarter 2022 Financial Results - Form 6-K
PU
2022Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results
AQ
2022Ascendis Pharma A/S Announces Second Quarter 2022 Financial Results and Business Update..
AQ
2022Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for Tra..
AQ
2022Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for Tra..
AQ
2022Ascendis Pharma - Positive Results from VISEN's Phase 3 Trial of Once-Weekly TransCon h..
AQ
2022Positive Results from VISEN's Phase 3 Trial of Once-Weekly TransCon hGH in China Consis..
AQ
2022Ascendis Pharma A/S Announces New Commercial Endocrinology Leadership Appointments
AQ
2022Ascendis Pharma A/S Reports First Quarter 2022 Financial Results
AQ
2022Ascendis Pharma A/S to Participate in the BofA Securities 2022 Healthcare Conference
AQ
2022Ascendis Pharma A/S Announces First Quarter 2022 Financial Results and Business Update ..
AQ
2022Ascendis Pharma A/s : Notice to convene Annual General Meeting 2022 - Form 6-K
PU
2022Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in Ma..
AQ
2022Ascendis Pharma A/s : Announces Proposed Convertible Senior Notes Offering - Form 6-K
PU
2022Ascendis Pharma Prices US$500.0 Million Convertible Senior Notes Offering
AQ
2022Ascendis Pharma Announces Proposed Convertible Senior Notes Offering
AQ
2022Ascendis Pharma A/s : Current Report by Foreign Issuer (Form 6-K)
PU
2022Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults wi..
AQ
2022Ascendis Pharma A/s : Reports Full Year 2021 Financial Results and Provides a Business Upd..
PU
2022Ascendis Pharma A/S Reports Full Year 2021 Financial Results and Provides a Business Up..
AQ
2022Ascendis Pharma A/S Announces Full Year 2021 Financial Results and Business Update Conf..
AQ
2022Ascendis Pharma A/S to Participate in the 11th Annual SVB Leerink Global Healthcare Con..
AQ
2022Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Gr..
AQ
2022Ascendis Pharma A/S Provides Update on Vision 3x3 Strategic Roadmap at 40th Annual J.P...
AQ
2022Ascendis Pharma A/S to Participate in 40th Annual J.P. Morgan Healthcare Conference
GL
2021Ascendis Pharma A/S Virtual R&D Program Update Highlights Continued Development Across ..
AQ
2021Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14
GL
2021Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forwar..
GL
2021Ascendis Pharma A/S to Participate in the Evercore ISI 4th Annual HealthCONx Conference
AQ
2021Ascendis Pharma A/S - Share Repurchase Program Update
AQ
2021Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon™ hGH for Patients..
GL
2021Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results - Form 6-K
PU
2021ASCENDIS PHARMA A/S INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEME..
PU
2021Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results
AQ
2021Ascendis Pharma A/S Presents New Non-Clinical Data†for TransCon™ TLR7/8 Agonist O..
AQ
2021Ascendis Pharma A/S - Share Repurchase Program Update
AQ
2021Ascendis Pharma A/S Announces Third Quarter 2021 Financial Results†and Business Update ..
AQ
2021Ascendis Pharma A/s : Notice to convene Extraordinary General Meeting - Form 6-K
PU
2021Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
PU
2021Ascendis Pharma A/s : Announces U.S. Commercial Launch of SKYTROFAģ (Lonapegsomatropin-tcg..
AQ
1  2  3  4  5Volgende
Volgende evenement op ASCENDIS PHARMA A/S